Moreover, there was a decrease in FOXC2 expression in KRASG12D-mutated CRC cells, which was reversed by MRTX1133 treatment suggesting that the KRASG12D mutation may negatively impact FOXC2 expression and that MRTX1133 could mitigate this effect (Fig. 8L). The gene discussed is FOXC2; the disease is colorectal carcinoma.